← Search & browse all drugs
NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › ANTIVERTIGO PREPARATIONS › Antivertigo preparations
cinnarizine
N07CA02
Adult Dosing
- Vestibular disorders: 25 mg three times daily
- Motion sickness: 25 mg 2 hours before travel, then 25 mg every 8 hours during travel
- Peripheral vascular disease: 75 mg two to three times daily
Pediatric Dosing
- Children 5-12 years: Half the adult dose (12.5 mg) for motion sickness or vestibular disorders
- Not recommended for children under 5 years
Indications
- Symptomatic treatment of labyrinthine disorders (vertigo, dizziness, tinnitus, nystagmus, nausea)
- Prevention and treatment of motion sickness
- Maintenance therapy for symptoms of cerebrovascular and peripheral vascular disease
Mechanism of Action
- Selective calcium channel blocker, predominantly affecting vascular smooth muscle and inner ear labyrinth
- Reduces the contractile response of blood vessels to vasoactive substances
- Possesses mild antihistaminic (H1), anticholinergic, and sedative properties
Contraindications
- Hypersensitivity to cinnarizine
- Acute phase of stroke or hemorrhage
- Parkinson's disease or history of extrapyramidal disorders
Adverse Reactions
- Drowsiness and somnolence
- Weight gain and increased appetite
- Gastrointestinal disturbance and dry mouth
- Extrapyramidal symptoms (tremor, rigidity, akathisia) with prolonged use in elderly patients
- Rare cases of cholestatic jaundice, lichen planus, and lupus-like skin reactions
Drug Interactions
- Central nervous system depressants (alcohol, barbiturates, narcotics, tricyclic antidepressants): Enhanced sedative effects
- Alcohol: Potential potentiation of psychomotor impairment
- Diagnostic use of anticholinergics may be altered
Curated Content: Needs Vetting Before Put to Clinical Use